NHS England has announced that Imnovid® (pomalidomide) for relapsed and refractory myeloma patients and Revlimid® (lenalidomide) for treatment at first relapse will no longer be available via the Cancer Drugs Fund (CDF) following a recent reassessment of the cancer drugs being funded this way. This applies only to patients in England, which will take effect from 1 November 2015, and does not affect those currently receiving the treatments. The removal of Imnovid and Revlimid from the CDF puts patients in England at a disadvantage compared to the rest of the UK – patients in Scotland have access to both drugs on the NHS and in Wales, patients can access pomalidomide on the NHS following its recent approval by the All Wales Medicines Strategy Group (AWMSG).

Read full article